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Abstract
Background: Ovarian fibrosarcomas are very rare tumors, and therefore, few case studies have evaluated the
prognostic factors of this disease. To our knowledge, this study represents the largest study to evaluate the clinical
and pathologic factors associated with ovarian fibrosarcoma patients.
Methods: Thirty-one cases of ovarian fibrosarcoma were retrospectively reviewed, which included medical records
for eight patients, and 23 published case reports from 1995 through 2009. Patient treatment regimens included
total hysterectomy with bilateral adnexectomy and an omentectomy (BAO) (n = 9), oophorectomy (OR) (n = 8),
chemotherapy (CT) (n = 1), BAO followed by chemotherapy (BAO+CT) (n = 11), BAO followed by radiotherapy
(BAO+RT) (n = 1), and oophorectomy followed by radiotherapy (OR + RT) (n = 1).
Results: The patients of this cohort were staged according to the guidelines of the Federation of Gynecology and
Obstetrics (FIGO), with 15, 6, 9, and 1 stage I-IV cases identified, respectively. Mitotic count values were also
evaluated from 10 high-power fields (HPFs), and 3 cases had an average mitotic count < 4, 18 cases were between
4 and 10, and 10 cases had an average mitotic count value ≥ 10. The Ki-67 (MIB-1) proliferation index values were
grouped according to values that as follows: < 10% (n = 5), between 10% and 50% (n = 9), and ≥ 50% (n = 5).
Positive expression of vimentin (100%, 22/22) and negative expression of CD117 (0%, 5/5) were also detected.
Moreover, expression of smooth muscle actin (2/18), desmin (1/13), epithelial membrane antigen (0/11), S-100
(1/19), CD99 (0/6), CD34 (1/5), a-inhibin (7/15), estrogen receptor (1/6), and progesterone receptor (1/6) were
reported for subsets of the cases examined. After a median follow-up period of 14 months (range, 2-120), the
2-year overall survival rates (OS) and disease-free survival (DFS) rates for all patients were 55.9% and 45.4%,
respectively. Cox proportional hazard regression analysis of survival showed that FIGO stage (P = 0.007) and
treatment (P = 0.008) were predictive of poor prognosis. Furthermore, patients with stage I tumors that received
BAO+CT were associated with a better prognosis.
Conclusions: Mitotic activity, and cells positive for Ki-67 were identified as important factors in the diagnosis of
ovarian fibrosarcoma. Furthermore, FIGO stage and treatment modalities have the potential to be prognostic
factors of survival, with BAO followed by adjuvant chemotherapy associated with an improved treatment outcome.
Background
Ovarian brosarcomas primarily originate in the ovaries
[1], and are very rare tumors. Correspondingly, very
few cases of ovarian fibrosarcoma have been reported.
As aresult, ovarian fibrosarcomas can be difficult to
distinguish clinically and histologically from cellular
fibromas [1-3]. The malignant potential of ovarian fibro-
sarcomas are usually assessed based on observed growth
patterns, cellular atypia, and mitotic counts [2]. How-
ever, due to the low incidence of this disease, it is diffi-
cult to enroll a sufficient number of patients to evaluate
the prognostic factors associated with survival. Further-
more, since an optimal treatment strategy for this
aggressive tumor has not yet been identified, it is not
only difficult to treat patients with ovarian fibrosarcoma,
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than 2 years due to early metastasis via the bloodstream
and tumor recurrence [4]. As a result, the prognosis for
patients with fibrosarcoma is very poor [1,2,5], and
there are few reports regarding the long-term survival of
patients with ovarian fibrosarcoma.
Therefore, in this study, a retrospective multi-center
clinical trial was established to determine whether clini-
cal or pathologic prognostic factors can be identified for
patients with ovarian fibrosarcoma.
Methods
A total of 31 patients diagnosed with ovarian fibrosar-
coma were identified from various sources. Three of
these cases were treated at the First Affiliated Hospital,
Medical College of ShantouU n i v e r s i t y( G u a n gD o n g ,
China) and 5 cases were treated at the Cancer Center,
Sun Yat-sen University (Guang Dong, China). In addi-
tion, 5 case reports published in a Chinese journal
[6-10], and 18 cases reported in the PubMed database
between January 1995 and December 2009 were retro-
spectively examined. Institutional review board approval
was obtained from each of the participating centers.
Histopathologic diagnosis was based on morphologic
criteria and immunohistochemical staining. Patients from
t h eM e d i c a lC o l l e g eo fS h a n t o uU n i v e r s i t y( n=3 )a n d
the Cancer Center, Sun Yat-sen University (n = 5) were
staged according to the FIGO clinical staging system for
ovarian cancer, and included information from physical
examinations, chest X-rays, intravenous (i.v.) pyelogra-
phy, cystoscopy, sigmoidoscopy, abdomino-pelvic com-
puted tomography (CT) scans, or magnetic resonance
imaging (MRI). When suspicious findings were identified
on chest X-rays and/or during physical examination, a
CT scan of the chest and/or brain was performed.
Clinical and pathological variables analyzed included
patient age, tumor size, FIGO stage, symptoms, mitotic
events, immunohistochemical results, and treatment
modalities. The primary end point was any cancer-
related death. End points were calculated from the date
of surgery for the cases from the Medical College of
Shantou University and the Cancer Center, Sun Yat-sen
University, while a presumedd a t eo fs u r g e r yw a se s t i -
mated for the additional 23 cases reviewed from the
literature.
Overall survival (OS) and disease-free survival (DFS)
were evaluated using the Kaplan-Meier method and log-
rank tests. The Cox proportional hazards model was
used to estimate the independent factors prognostic for
OS and DFS. All analyses were carried out using SPSS
software (version 13.0, SPSS Inc., Chicago, IL), and a
significance level of 0.05 was used. All end points were
updated in March 2010.
Results
Clinical Features
In this cohort (n = 31), patient age ranged from 20 - 73
years, with a median age of 49 years (Table 1). For 6/25
(24%) patients, the ovarian fibrosarcomas were detected
during a routine gynecological examination. Alterna-
tively, 19/25 (76%) patients presented with abdominal
pain, vaginal bleeding, or notable pelvic swelling at a
hospital. For 6/31 cases that were reviewed from pub-
lished case reports, the details of presentation were not
provided [2]. FIGO staging of the tumors of this cohort
included 15 (49%) stage I cases, 6 (19%) stage II cases,
9 (29%) stage III cases, and 1 (3%) stage IV case. Corre-
spondingly, treatment for this cohort varied. Nine
patients were treated with a total hysterectomy with
bilateral adnexectomy and an omentectomy (BAO),
8 patients underwent an oophorectomy (OR), 1 patient
received chemotherapy (CT), 11 patients received BAO
followed by a chemotherapy (BAO+CT), and 2 patients
underwent BAO followed by treatment with radiother-
apy (BAO+RT). After a median follow-up period of 14
months (range, 2-120), the 2-year OS rates and 2-year
DFS rates for this cohort were 55.9% and 45.4%, respec-
tively (Figure 1A).
Pathologic Features
The tumors detected ranged from 5.2 - 23 cm for the
greatest diameter (average, 11.5). The specimens from
the Medical College of Shantou University (n = 3) and the
Cancer Center, Sun Yat-sen University (n = 5) were solid
tumors, and a cut of the surface of the tumor revealed
tan-yellow discoloration and partial necrosis. Microscopi-
cally, spindle-shaped cells were densely arranged in a whir-
ling pattern, with myxoid stroma and hemorrhages
observed in some areas. In general, the tumor cells con-
tained elongated hyperchromatic nuclei, and in some
areas, round or oval nuclei were observed. In all 31 cases,
the mitotic value ranged from 1 - 25 mitoses per 10 high
powered fields (HPFs) examined. For example, 3/31 (10%)
cases had a mitotic count < 4 per 10 HPFs, while for 18/
31 (58%) cases the mitotic count was ≥ 4 and < 10 per 10
HPFs, and for 10/31 (32%) cases the mitotic count was
≥ 10 per 10 HPFs. For a subset of cases, the Ki-67 (MIB-1)
proliferation index values were also available, and included
values of < 10% for 5 cases, ≥ 10% and < 50% for 9 cases,
and ≥ 50% up to 85% for 5 cases. Tumor cells from a sub-
set of cases were also associated with strong expression of
vimentin (22/22, 100%) and an absence of CD117 expres-
sion (0%, 5/5). Additional immunohistochemical assays
that were performed for a subset of the cases examined
included detection of smooth muscle actin (SMA) (2/18,
11%), desmin (1/13, 8%), epithelial membrane antigen
(EMA) (0/11, 0%), S-100 (1/19, 5%), CD99 (0/6, 0%),
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Page 2 of 9Table 1 The clinical and pathologic features of the ovarian fibrosarcoma cases examined
Reference Case
No.
Age Symptom FIGO
stage
Largest
diameter
(cm)
Mitoses/
10 HPFs
CD10 Ki-67
(MIB-1)
positive
Vimentin CD117 SMA Des EMA S-
100
CD99 CD34 a-
inhibin
ER PR CA125
U/ml
Therapy Recurrence Follow-
up
(months)
Interval
(months)
Site Treatment
China
Case 1 [6]
1 43 AP III c 10 ≥4 (-) 50%-
75%
(+) (-) (-) / / (-) (-) / (-) (-) (-) / OR 1 Pelvis BAO Died (4)
China
Case 2 [7]
2 39 AP I a 11 5~7 (-) 85% (+) / (-) (-) (-) (-) (-) / (-) (-) (-) / BAO NP NP NP TF (14)
China
Case 3
3 53 NP I a 10 3~7 / / (+) / (-) (-) (-) (-) (-) / (-) (-) (-) 68.45 BAO NP NP NP TF (12)
China
Case 4
4 20 NP II a 7 3~5 / 15% (+) (-) (-) (-) (-) (-) (-) / (-) / / / BAO 6 Pelvis CT Died (10)
China
Case 5 [8]
5 56 NP III c 16 13 (-) 25% (+) (-) (-) (-) (-) (-) (-) (-) / / / <35 BAO+(IA
+DTIC)
NP NP NP TF (8)
China
Case 6 [9]
6 43 NP I a 5.7 16 (-) >10% (+) / (-) / / (-) / (-) (+) / / <35 BAO
+PVB
NP NP NP TF (7)
China
Case 7 [10]
7 21 AP III b 15 ≥4 /> 1 0 % ( + ) / ///// / / / / /O R 3 P e lvis NP Died (6)
China
Case 8
8 66 AP II b 11 8 / 15% (+) / (-) (-) (-) (-) / / (-) / / / BAO 10 Sigmoid SS+CT Died (23)
China
Case 9
93 7 A P I I c / ≥4 (+) 20% (+) (-) (-) (-) (-) (-) / (-) (-) (-) (-) 198 BAO+(IA
+DTIC)
NP NP NP TF (15)
China
Case 10
10 44 AP III b 13 23 (-) 75% (+) / (-) / / (-) / / (-) / / / OR 1 Pelvis NP Died (3)
China
Case 11
1 1 5 2 A P I I b 1 2 1 4 / < 5 % / / ///// / / / / /B A O
+IAP
16 Pelvis CT Alive
with
tumor
(34)
China
Case 12
12 48 NP I a 8 3~4 (-) <5% (+) / (-) (-) / (-) / / (-) / / / BAO
+IAP
NP NP NP TF (45)
China
Case 13
13 61 AP III b 15 18 / 60% (+) / (+) (-) (-) (-) / / (+) / / / OR 2 Pelvis NP Died (11)
Lee et al.
[17]
1 4 6 9 V B I 6 6 ~ 8 /> 1 0 % / / ///// / ( + )/ / /B A O / / / /
Kruger et al.
[18]
15 32 NP I 7 8 / 5%-10% / / / (-) (-) (-) / (-) / / / 116.1 OR NP NP NP TF (12)
Choi et al.
[19]
16 44 AP I a 18 17 / <1% (+) / (-) / / (-) / / / (-) (-) / BAO+AP NP NP NP TF (120)
17 34 AP I b 13 8 / 20% (+) / (-) / / (-) / / / (+) (+) 26.5 BAO
+(VP16
+IP)
NP NP NP TF (60)
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9Table 1 The clinical and pathologic features of the ovarian fibrosarcoma cases examined (Continued)
Testa et al.
[20]
1 8 4 4 N P I I I b / 7 / ( + ) / ///// / ( + )/ / /B AO+IA NP NP NP TF (50)
1 9 5 0 N P I a / 5 ~ 7 / 1 2 % ( + ) / ///// / ( + )/ / /B A O N P N P N P T F ( 5 )
Jimenez
et al. [21]
20 55 VB I c 23 <1-2 / 60% (+) (-) (-) / / / / / / / / / BAO+IA 14 Liver SS Alive
with
tumor
(14)
Celyk et al.
[5]
21 49 AP III c 12 ≥4 / ? (+) / / (+) / (+) / / / / / 300 BAO+TP 36 Pelvis, liver NP Died (42)
McCluggage
et al. [22]
22 61 AP III c 7 12~15 / / (+) / (-) (-) / (-) / / (+) / / 196 BAO+CT / / / /
P r a t e t a l . [ 2 ] 2 3 6 1 / I a 1 0 4 / / / / ///// / / / / /B AO+RT 18 Liver NP Died (18)
2 4 5 9 / I I b / 8 / / / / ///// / / / / /B A O 1 S i gmoid SS+RT Died (4)
2 5 4 2 / I I b / 2 5 / / / / ///// / / / / /B A O 1 U r e t e r R T A live
with
tumor
(13)
2 6 6 5 / I a / 1 0 / / / / ///// / / / / /O R 6 P e lvis NP Died (13)
2 7 7 3 / I I I 6 7 / / / / ///// / / / / /C T 2 P e l v i s ,
Peritoneum
CT Died (2)
2 8 4 9 / I a / 5 / / / / ///// / / / / /B A O 4 4 P e l v i s ,
Peritoneum
CT Died (48)
Fukuda et al.
[23]
29 54 AP I a 22 3~6 / 5.4%-
8.2%
(+) / (-) (-) (-) (-) / (+) (+) / / / OR 14 Pelvis SS+AP TF (22)
Iiboshi et al.
[24]
30 38 NP I a 5.2 20~25 / / (+) / (-) / (-) (-) / / / / / / OR NP NP NP TF (24)
Watanabe et
al. [25]
31 44 NP IV 12 <4 / / (+) / (+) (-) (-) (-) (-) / / / / / OR+RT / / / Died (4)
NP, not performed; TF, tumor-free; AP (Symptom), abdominal pain; VB, vaginal bleeding; OR, oophorectomy; BA0, a total hysterectomy with bilateral adnexectomy and an omentectomy; CT, chemotherapy; RT,
radiotherapy; SS, second surgery; IA, ifosfamide + adriamycin; DTIC, dacarbazine; PVB, Cisplatin + Vincristine + Bleomycin; IAP, ifosfamide + adriamycin + Cisplatin; AP, adriamycin + Cisplatin; VP-16, etoposide; TP,
paclitaxel + cisplatin.
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9Figure 1 Kaplan-meier survival curves for the clinicopathologic factors of patients with ovarian fibrosarcoma. (A) Survival curves for the
OS and DFS rates associated with 31 patients diagnosed with ovarian fibrosarcoma as indicated. (B) Survival curves for OS and DFS rates in
relation to various FIGO stages of ovarian fibrosarcoma as indicated. (C) Survival curves for OS and DFS rates in relation to the percentage of Ki-
67-positive cells detected (< 10% shown in red and ≥ 10% shown in blue). (D) Survival curves of OS and DFS rates associated with BAO/OR/CT/
OR + RT/BAO+RT (shown in blue) vs. BAO + CT alone (shown in red).
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Page 5 of 9CD34 (1/5, 20%), a-inhibin (7/15, 47%), estrogen receptor
(ER) (1/6, 17%), and progesterone receptor (PR) (1/6, 17%)
(Table 1).
Univariate and multivariate analysis
Various clinicopathologic variables were also evaluated
to identify potential prognostic factors for survival. Uni-
variate analysis identified FIGO stage, Ki-67-positive
cells, and therapy to be associated with the prognosis of
patients with ovarian fibrosarcomas (P <0 . 0 5 ) .T h e2 -
year OS and DFS rates for FIGO stage Ia-Ic, or FIGO
stage IIa-IIIc, were 77.1% and 36.2% (P = 0.014), and
68.4% and 22.9% (P = 0.003), respectively in each case
(Figure 1B). When the 2-year OS rate was evaluated in
relation to the percentage of Ki-67-positive cells, the
survival of patients with < 10% vs. ≥ 10% of Ki-67 posi-
tive cells was 100% and 27.2%, respectively (P = 0.042).
Similarly, the 2-year DFS rate for the same categories of
Ki-67 were 66.7% and 36.3%, respectively (P =0 . 0 7 6 )
(Figure 1C). In terms of treatments received, the 2-year
OS rate for patients receiving BAO, OR, or BAO + RT,
was 27.9%, while patients receiving BAO + CT had a
2-year OS rate of 100% (P = 0.002). For the same cate-
gories of patient treatment, the 2-year DFS rates were
28.5% and 72.9%, respectively (P = 0.008) (Figure 1D).
In contrast, patient age (2-year OS, P =0 . 3 4 8 ;2 - y e a r
DFS P = 0.224), tumor size (2-year OS, P =0 . 7 9 3 ;
2-year DFS, P = 0.666), and mitoses/10 HPFs (2-year
OS, P = 0.426; 2-year DFS P = 0.830) were not found to
be prognostic for survival (Table 2).
A role for multimodal therapy in patient prognosis
w a sa l s oe x a m i n e d .D u et ot h el i m i t e dn u m b e r so f
patients included in this study, the available cases were
divided into two groups: those receiving BAO, OR, CT,
OR + RT, or BAO+RT therapy, and those receiving
BAO+CT. For these groups, 12/20 (60%) patients vs
1/11 (9.1%) patient died of their disease within 5 years,
respectively. Furthermore, patients in the former group
were associated with a poorer prognosis and a 2-year
OS rate of 27.9%, compared to those in the latter group
that were associated with a 2-year OS rate of 100% [HR,
0.07; 95% CI, 0.008-0.574; P = 0.013] (Figure 1D).
Cox proportional hazard regression analysis of patient
survival based on clinical and pathologic factors was
also performed. Multivariate analysis identified FIGO
stage (Ia- Ic vs. IIa- IIIc, Hazard Ratio (HR) = 0.231,
95% CI of ratio = [0.072, 0.743], P = 0.007) and treat-
ment (BAO/OR/CT/OR + RT/BAO+RT vs. BAO+CT,
HR = 6.516, 95% CI of ratio = [1.974, 21.52], P =0 . 0 0 8 )
to be significant independent prognostic factors for sur-
vival. In contrast, patient age, tumor size, mitosis events
per 10 HPFs, and percentage of Ki-67-positive cells
present were not found to be significant independent
prognostic factors for survival (Table 2).
Discussion
Ovarian fibrosarcoma is an extremely rare entity
[1,2,11], and is considered to arise directly from stro-
mal cells around the sex cord of ovarian follicles. How-
ever, the malignant transformation of a previous
fibroma is also believed to be a potential origin of
ovarian fibrosarcoma as well. These tumors can occur
at any age, although they are mostly diagnosed in
menopausal and postmenopausal women. Clinically,
the presentation of this disease includes pelvic pain,
abdominal enlargement, or awareness of an abdominal
mass [1-3]. In addition, the majority of tumors exhibit
areas of necrosis and haemorrhage, capsular disrup-
tion, as well as infiltrative margins that lead to adhe-
sion of the tumor with other pelvic organs. For the 31
cases compared in this study, the median patient age
was 49 years, and 19 patients presented at a hospital
with abdominal pain, vaginal bleeding, or notable pel-
vic swelling.
Previous studies have reported a moderate to marked
degree of pleomorphism to be associated with ovarian
fibrosarcomas, with the number of mitotic figures
observed ranging from 4-25 per 10 HPFs [1,2,12,13].
For example, in an evaluation of 17 cases of malignant,
as well as cellular, fibromatous tumors of the ovary,
Prat and Scully [2] classifiedt h e s ec a s e si n t ot w oc a t e -
gories, those with 1-3 mitotic figures per 10 HPFs,
which were designated as cellular fibromas, vs. those
with greater than 4 mitoses per 10 HPFs, which were
designated as fibrosarcomas. Usually, these criteria
would not present a problem. However, the results of a
recent study by Irving et al. indicate that mitotic activity
is not a unique criteria for malignancy. For example,
cases of ovarian fibromatous tumors were found to be
associated with a very high mitotic count, whereas blunt
nuclei, which usually do not exhibit an aggressive
course of disease, were diagnosed as ‘mitotically active
cellular fibromas’ instead of fibrosarcomas [14]. In our
study, 18 cases were associated with a mitotic count ≥4
or <10, and 10 cases had a mitotic count ≥10. Only
three cases had a mitotic count <4. However, in the
latter cases, one patient developed a metastasis in the
liver one year later, one patient died 4 months following
the surgery, and one patient was tumor-free for 45
months.
In work by Tsuji et al. [3], the Ki-67 index values for
fibrosarcomas were found to be higher than the Ki-67
values for fibromas. In doubtful cases, an assessment of
the proliferative activity according to the MIB-1 labeling
index was found to improve the accuracy of the diagnosis
[3]. In the present study, there were three doubtful cases.
However, when morphology, immunohistochemical
results, and proliferative features were examined, a clear
diagnosis of fibrosarcoma could be made. Furthermore,
Huang et al. BMC Cancer 2010, 10:585
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Page 6 of 9Table 2 The 2-year OS and DFS rates associated with ovarian fibrosarcoma patients and Cox proportional hazard regression analysis of patient survival
based on clinical and pathologic factors
Variables Case
(%)
2 year’s rate 2 year’s rate Cox (OS) Cox (DFS)
Univariate Multivariate Univariate Multivariate
OS X2 P DFS X2 P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (years)
<45 15 (48.4) 66 60
≥45 16 (51.6) 45.4 0.879 0.348 27.8 1.476 0.224 1.731 (0.540-5.545) 0.356 1.882 (0.658-5.382) 0.238
FIGO stage
I a - I c 14 (45.2) 77.1 68.4
II a - III c 17 (54.8) 36.2 6.041 0.014 22.9 8.964 0.003 4.525 (1.210-
16.916)
0.025 10.156 (2.021-
51.023)
0.005 4.914 (1.538-
15.704)
0.007 18.761 (1.674-
210.288)
0.017
Largest diameter (cm)
<10 11 (45.8) 43.2 44.4
≥10 13 (54.2) 54.7 0.069 0.793 38.9 0.187 0.666 0.844 (0.236-3.014) 0.794 1.302 (0.389-4.360) 0.669
Mitoses/10 HPFs
<4 22 (71.0) 49.7 48
≥4 9 (29.0) 70 0.632 0.426 41.7 0.046 0.83 0.545 (0.119-2.499) 0.435 1.132 (0.358-3.575) 0.833
Ki-67 (MIB-1)-positive
<10 5 (26.3) 100 66.7
≥10 14 (73.7) 27.2 4.148 0.042 36.3 3.138 0.076 51.792 (0.053-5058) 0.261 5.862 (0.668-
51.416)
0.11
Therapy
BAO/OR/CT/BAO+RT/OR
+RT
20 (64.5) 27.9 28.5
BAO+CT 11 (35.5) 100 9.462 0.002 72.9 6.97 0.008 0.070 (0.008-0.574) 0.013 0.029 (0.003-0.319) 0.004 0.197 (0.052-0.741) 0.016 0.071 (0.005-0.992) 0.049
HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival; CS, cytoreductive surgery; OR, oophorectomy; CT, chemotherapy; RT, radiotherapy; BA0, a total hysterectomy with bilateral
adnexectomy and an omentectomy.
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9high levels of Ki67 (MIB-1) expression were consistent
with a malignant diagnosis, despite a low visual mitotic
rate that was also observed. However, when a multivari-
ate analysis was performed, the presence of Ki-67-posi-
tive cells was not found to be a significant independent
prognostic factor for survival.
The optimization of treatment strategies to improve
patient outcome for patients diagnosed with an
aggressive tumor such as ovarian fibrosarcoma, have
not been identified. As a result, most patients experi-
ence a fatal outcome due to early metastasis via the
bloodstream and tumor recurrences that usually occur
within 2 years of diagnosis. Furthermore, there is no
universally accepted treatment modality for ovarian
fibrosarcoma as there is for epithelial ovarian cancers.
For example, surgical resection for an ovarian fibro-
sarcoma can range from a simple adnexectomy, to a
total hysterectomy with bilateral adnexectomy and an
omentectomy. In many cases, post-surgical adjuvant
chemotherapy or radiation is also required [15,16].
After reviewing several studies, Miles et al. reported
that surgery did not prevent the recurrence of this
disease regardless of the extent of surgery, and adju-
vant chemotherapy and radiation therapy did not
influence patient survival [16]. Moreover, there are
few reports to indicate that adjuvant chemotherapy
may improve patient survival rates, although Huang et
al. reported that the use of MAID (mesna, doxorubi-
cin, ifosfamide, and DTIC) for the treatment of ovar-
ian fibrosarcoma has shown potential for prolonging
patient survival [4]. Moreover, Celyk et al. reported
that a regimen of paclitaxel plus cisplatin can improve
the prognosis for patients with advanced stage tumors
in some cases [11]. In the present study, multimodal
therapy was evaluated for its capacity to improve
patient prognosis, and BAO surgery followed by che-
motherapy was associated with the greatest improve-
ment in prognosis.
Conclusion
In conclusion, high rates of Ki-67-positive cells, repre-
senting a high proliferation rate, may contribute to the
malignant characteristic associated with ovarian fibrosar-
comas. However, this is in contrast with the low visual
mitotic rate associated with these tumors. The results of
the present study indicate that FIGO stage and treat-
ment modality may represent prognostic factors for
patient survival, and BAO followed by adjuvant che-
motherapy is associated with an improved treatment
outcome. In addition, although this study was retrospec-
tive in design, and included a limited number of
patients, it is one of the largest series reported to date.
As such, these results provide valuable insight into a
challenging and rare disease, and contribute to the
limited body of knowledge that is currently available for
this aggressive tumor type.
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